Community participants with COPD or bronchiectasis and at risk of Respiratory Viral Infections including SARS-CoV-2: An open-label, multicentre feasibility study of an inhaled nitric oxide generating solution (RESP301)
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Nitric oxide (Primary)
- Indications Bronchiectasis; Chronic obstructive pulmonary disease; COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms CORVIS
- Sponsors Thirty respiratory
- 21 Aug 2023 Status changed from suspended to discontinued.
- 12 Dec 2022 Status changed from recruiting to suspended.
- 17 Dec 2021 Planned End Date changed from 1 Dec 2022 to 1 Apr 2023.